Data from the multinational Prospective Lynch syndrome Database have suggested that older Lynch syndrome carriers with pathogenic MLH1 or MSH2 mutations are at particular risk for upper gastrointestinal cancers, with such individuals having a 7.1% and 7.7% cumulative risk of gastric cancer by age 75, respectively, with a 61% 5-year survival rate [7]. The gene discussed is MSH2; the disease is gastric cancer.